Sanibel Captiva Trust Company Inc. Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

Sanibel Captiva Trust Company Inc. grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 73.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 15,568 shares of the company’s stock after buying an additional 6,575 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Novo Nordisk A/S were worth $1,339,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brooklyn Investment Group boosted its holdings in Novo Nordisk A/S by 1,634.3% in the 4th quarter. Brooklyn Investment Group now owns 2,931 shares of the company’s stock valued at $252,000 after purchasing an additional 2,762 shares in the last quarter. Sax Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $382,000. Merit Financial Group LLC boosted its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Merit Financial Group LLC now owns 19,240 shares of the company’s stock valued at $1,655,000 after buying an additional 10,550 shares in the last quarter. Boston Common Asset Management LLC grew its holdings in Novo Nordisk A/S by 5.9% during the fourth quarter. Boston Common Asset Management LLC now owns 53,260 shares of the company’s stock worth $4,581,000 after acquiring an additional 2,967 shares during the period. Finally, Wealthcare Advisory Partners LLC raised its position in Novo Nordisk A/S by 74.3% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 25,425 shares of the company’s stock worth $2,187,000 after acquiring an additional 10,839 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent analyst reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Down 5.2 %

Shares of NYSE:NVO opened at $78.74 on Friday. The company has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45. The stock’s fifty day simple moving average is $97.76 and its 200-day simple moving average is $117.23. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.